An Open-Label, Randomized, Controlled Phase-II Trial Evaluating the Efficacy and Safety of EndoTAG-1 in Triple Receptor Negative Breast Cancer Patients.

Trial Profile

An Open-Label, Randomized, Controlled Phase-II Trial Evaluating the Efficacy and Safety of EndoTAG-1 in Triple Receptor Negative Breast Cancer Patients.

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Apr 2014

At a glance

  • Drugs Paclitaxel (Primary)
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Sponsors MediGene AG
  • Most Recent Events

    • 01 Apr 2014 Results published in the Annals of Oncology.
    • 04 Jan 2012 Actual end date Mar 2011 added as reported by ClinicalTrials.gov.
    • 09 Dec 2011 Results presented at the 34th Annual San Antonio Breast Cancer Symposium, according to a MediGene media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top